Reynald Castañeda / endpoints - Paul Hudson is stepping down from his post as CEO of Sanofi, and his last day will be Feb. 17. The French drugmaker's board decided not to renew Hudson's mandate on ...
AI Summary: Sanofi’s board has opted not to renew Paul Hudson’s tenure, installing Belén Garijo as the new chief executive amid mixed reactions. The leadership swap arrives as the French drugmaker faces pipeline pressures and investor impatience—expect strategic shuffles, belt‑tightening and plenty of corporate soul‑searching with a side of investor scrutiny.
First-in-human trial primes immune system to accept donor livers / 6 wks
Experimental therapy significantly reduces Parkinson’s toxic protein in early trial / 7 wks
Keratin 16 restrains skin inflammation and may guide treatments / 7 wks
Belzutifan combinations highlighted at ASCO GU improve RCC outcomes / 2 months
FDA lifts holds on Intellia’s Phase 3 gene-editing trials / 2 months
Rezatapopt shows proof-of-concept reactivating mutant p53 in patients / 2 months
Perioperative enfortumab vedotin plus pembrolizumab improves outcomes in MIBC / 3 months
StackHealth RSS

StackHealth Time Machine
NorthFeed Inc. Terms and Conditions / Privacy Policy
Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.